YY1 and neoplasm: Galiximab, a chimeric monoclonal antibody that targets CD80 and is currently in phase II clinical trials for the treatment of follicular lymphoma [205], could also downregulate YY1 expression by inhibiting NF-κB, which resulted in the induction of apoptosis in tumor cells [206].